What is the projected market valuation for the Arthropod-Borne Viral Infections Testing Market in 2035?

The projected market valuation for the Arthropod-Borne Viral Infections Testing Market in 2035 is 5.41 USD Billion. Read More

Which companies are considered key players in the Arthropod-Borne Viral Infections Testing Market?

Key players in the market include Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Bio-Rad Laboratories, Qiagen, Becton Dickinson and Company, Hologic, Inc., and Cepheid. Read More

What is the expected CAGR for the Arthropod-Borne Viral Infections Testing Market during the forecast period 2025 - 2035?

The expected CAGR for the Arthropod-Borne Viral Infections Testing Market during the forecast period 2025 - 2035 is 7.84%. Read More

Which test type segment is projected to have the highest valuation by 2035?

The Molecular Testing segment is projected to reach a valuation of 1.99 USD Billion by 2035. Read More

How does the valuation of the Serological Testing segment change from 2024 to 2035?

The Serological Testing segment valuation increases from 0.707 USD Billion in 2024 to 1.54 USD Billion in 2035. Read More

What is the projected valuation for the Dengue Virus testing segment by 2035?

The projected valuation for the Dengue Virus testing segment is 1.95 USD Billion by 2035. Read More

Which end user segment is expected to see the most growth by 2035?

The Hospitals segment is expected to grow to a valuation of 1.95 USD Billion by 2035. Read More

What is the anticipated valuation for the Culture Testing segment in 2035?

The anticipated valuation for the Culture Testing segment is 0.82 USD Billion in 2035. Read More

How does the projected valuation for the Public Health Organizations segment change from 2024 to 2035?

The Public Health Organizations segment is expected to increase from 0.354 USD Billion in 2024 to 1.16 USD Billion in 2035. Read More

Arthropod Borne Viral Infections Testing Market

Q: What was the overall market valuation for the Arthropod-Borne Viral Infections Testing Market in 2024?

The overall market valuation for the Arthropod-Borne Viral Infections Testing Market in 2024 was 2.358 USD Billion. Read More

ID: MRFR/HC/34121-HCR

128 Pages

Rahul Gotadki

Last Updated: May 18, 2026

Arthropod-Borne Viral Infections Testing Market Research Report By Test Type (Molecular Testing, Serological Testing, Antigen Testing, Culture Testing), By Infection Type (Dengue Virus, Zika Virus, West Nile Virus, Chikungunya Virus), By End User (Hospitals, Diagnostic Laboratories, Research Institutions, Public Health Organizations), By Sample Type (Blood, Urine, Saliva, Tissue) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Test Type (USD Billion)
  1. 4.1.1 Molecular Testing
  2. 4.1.2 Serological Testing
  3. 4.1.3 Antigen Testing
  4. 4.1.4 Culture Testing
2. 4.2 Healthcare, BY Infection Type (USD Billion)
  1. 4.2.1 Dengue Virus
  2. 4.2.2 Zika Virus
  3. 4.2.3 West Nile Virus
  4. 4.2.4 Chikungunya Virus
3. 4.3 Healthcare, BY End User (USD Billion)
  1. 4.3.1 Hospitals
  2. 4.3.2 Diagnostic Laboratories
  3. 4.3.3 Research Institutions
  4. 4.3.4 Public Health Organizations
4. 4.4 Healthcare, BY Sample Type (USD Billion)
  1. 4.4.1 Blood
  2. 4.4.2 Urine
  3. 4.4.3 Saliva
  4. 4.4.4 Tissue
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Abbott Laboratories (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Roche Diagnostics (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Thermo Fisher Scientific (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bio-Rad Laboratories (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Qiagen (DE)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Becton Dickinson and Company (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Hologic, Inc. (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Cepheid (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TEST TYPE
4. 6.4 US MARKET ANALYSIS BY INFECTION TYPE
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 US MARKET ANALYSIS BY SAMPLE TYPE
7. 6.7 CANADA MARKET ANALYSIS BY TEST TYPE
8. 6.8 CANADA MARKET ANALYSIS BY INFECTION TYPE
9. 6.9 CANADA MARKET ANALYSIS BY END USER
10. 6.10 CANADA MARKET ANALYSIS BY SAMPLE TYPE
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY TEST TYPE
13. 6.13 GERMANY MARKET ANALYSIS BY INFECTION TYPE
14. 6.14 GERMANY MARKET ANALYSIS BY END USER
15. 6.15 GERMANY MARKET ANALYSIS BY SAMPLE TYPE
16. 6.16 UK MARKET ANALYSIS BY TEST TYPE
17. 6.17 UK MARKET ANALYSIS BY INFECTION TYPE
18. 6.18 UK MARKET ANALYSIS BY END USER
19. 6.19 UK MARKET ANALYSIS BY SAMPLE TYPE
20. 6.20 FRANCE MARKET ANALYSIS BY TEST TYPE
21. 6.21 FRANCE MARKET ANALYSIS BY INFECTION TYPE
22. 6.22 FRANCE MARKET ANALYSIS BY END USER
23. 6.23 FRANCE MARKET ANALYSIS BY SAMPLE TYPE
24. 6.24 RUSSIA MARKET ANALYSIS BY TEST TYPE
25. 6.25 RUSSIA MARKET ANALYSIS BY INFECTION TYPE
26. 6.26 RUSSIA MARKET ANALYSIS BY END USER
27. 6.27 RUSSIA MARKET ANALYSIS BY SAMPLE TYPE
28. 6.28 ITALY MARKET ANALYSIS BY TEST TYPE
29. 6.29 ITALY MARKET ANALYSIS BY INFECTION TYPE
30. 6.30 ITALY MARKET ANALYSIS BY END USER
31. 6.31 ITALY MARKET ANALYSIS BY SAMPLE TYPE
32. 6.32 SPAIN MARKET ANALYSIS BY TEST TYPE
33. 6.33 SPAIN MARKET ANALYSIS BY INFECTION TYPE
34. 6.34 SPAIN MARKET ANALYSIS BY END USER
35. 6.35 SPAIN MARKET ANALYSIS BY SAMPLE TYPE
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY TEST TYPE
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY INFECTION TYPE
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY END USER
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY SAMPLE TYPE
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY TEST TYPE
42. 6.42 CHINA MARKET ANALYSIS BY INFECTION TYPE
43. 6.43 CHINA MARKET ANALYSIS BY END USER
44. 6.44 CHINA MARKET ANALYSIS BY SAMPLE TYPE
45. 6.45 INDIA MARKET ANALYSIS BY TEST TYPE
46. 6.46 INDIA MARKET ANALYSIS BY INFECTION TYPE
47. 6.47 INDIA MARKET ANALYSIS BY END USER
48. 6.48 INDIA MARKET ANALYSIS BY SAMPLE TYPE
49. 6.49 JAPAN MARKET ANALYSIS BY TEST TYPE
50. 6.50 JAPAN MARKET ANALYSIS BY INFECTION TYPE
51. 6.51 JAPAN MARKET ANALYSIS BY END USER
52. 6.52 JAPAN MARKET ANALYSIS BY SAMPLE TYPE
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY TEST TYPE
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY INFECTION TYPE
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY END USER
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY SAMPLE TYPE
57. 6.57 MALAYSIA MARKET ANALYSIS BY TEST TYPE
58. 6.58 MALAYSIA MARKET ANALYSIS BY INFECTION TYPE
59. 6.59 MALAYSIA MARKET ANALYSIS BY END USER
60. 6.60 MALAYSIA MARKET ANALYSIS BY SAMPLE TYPE
61. 6.61 THAILAND MARKET ANALYSIS BY TEST TYPE
62. 6.62 THAILAND MARKET ANALYSIS BY INFECTION TYPE
63. 6.63 THAILAND MARKET ANALYSIS BY END USER
64. 6.64 THAILAND MARKET ANALYSIS BY SAMPLE TYPE
65. 6.65 INDONESIA MARKET ANALYSIS BY TEST TYPE
66. 6.66 INDONESIA MARKET ANALYSIS BY INFECTION TYPE
67. 6.67 INDONESIA MARKET ANALYSIS BY END USER
68. 6.68 INDONESIA MARKET ANALYSIS BY SAMPLE TYPE
69. 6.69 REST OF APAC MARKET ANALYSIS BY TEST TYPE
70. 6.70 REST OF APAC MARKET ANALYSIS BY INFECTION TYPE
71. 6.71 REST OF APAC MARKET ANALYSIS BY END USER
72. 6.72 REST OF APAC MARKET ANALYSIS BY SAMPLE TYPE
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY TEST TYPE
75. 6.75 BRAZIL MARKET ANALYSIS BY INFECTION TYPE
76. 6.76 BRAZIL MARKET ANALYSIS BY END USER
77. 6.77 BRAZIL MARKET ANALYSIS BY SAMPLE TYPE
78. 6.78 MEXICO MARKET ANALYSIS BY TEST TYPE
79. 6.79 MEXICO MARKET ANALYSIS BY INFECTION TYPE
80. 6.80 MEXICO MARKET ANALYSIS BY END USER
81. 6.81 MEXICO MARKET ANALYSIS BY SAMPLE TYPE
82. 6.82 ARGENTINA MARKET ANALYSIS BY TEST TYPE
83. 6.83 ARGENTINA MARKET ANALYSIS BY INFECTION TYPE
84. 6.84 ARGENTINA MARKET ANALYSIS BY END USER
85. 6.85 ARGENTINA MARKET ANALYSIS BY SAMPLE TYPE
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TEST TYPE
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY INFECTION TYPE
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY SAMPLE TYPE
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TEST TYPE
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY INFECTION TYPE
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY END USER
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY SAMPLE TYPE
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TEST TYPE
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY INFECTION TYPE
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY END USER
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY SAMPLE TYPE
99. 6.99 REST OF MEA MARKET ANALYSIS BY TEST TYPE
100. 6.100 REST OF MEA MARKET ANALYSIS BY INFECTION TYPE
101. 6.101 REST OF MEA MARKET ANALYSIS BY END USER
102. 6.102 REST OF MEA MARKET ANALYSIS BY SAMPLE TYPE
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY TEST TYPE, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY TEST TYPE, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY INFECTION TYPE, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY INFECTION TYPE, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY END USER, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY SAMPLE TYPE, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY SAMPLE TYPE, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.2.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.3.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.3.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.4.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.4.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.5.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.5.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.6.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.6.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.7.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.7.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.8.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.8.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.9.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.9.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.10.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.10.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.11.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.11.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.12.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.12.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.13.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.13.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.14.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.14.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.15.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.15.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.16.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.16.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.17.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.17.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.18.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.18.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.19.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.19.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.20.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.20.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.21.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.21.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.22.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.22.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.23.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.23.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.24.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.24.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.25.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.25.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.26.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.26.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.27.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.27.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.28.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.28.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.29.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.29.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY INFECTION TYPE, 2025-2035 (USD Billion)
  3. 7.30.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.30.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Arthropod Borne Viral Infections Testing Market Segmentation

Arthropod Borne Viral Infections Testing Market By Test Type (USD Billion, 2025-2035)

Molecular Testing
Serological Testing
Antigen Testing
Culture Testing

Arthropod Borne Viral Infections Testing Market By Infection Type (USD Billion, 2025-2035)

Dengue Virus
Zika Virus
West Nile Virus
Chikungunya Virus

Arthropod Borne Viral Infections Testing Market By End User (USD Billion, 2025-2035)

Hospitals
Diagnostic Laboratories
Research Institutions
Public Health Organizations

Arthropod Borne Viral Infections Testing Market By Sample Type (USD Billion, 2025-2035)

Blood
Urine
Saliva
Tissue

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035